A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH



CBI Capabilities with a focus on Oncology Studies

Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com

COMPARATIVE BIOSCIENCES, INC.

A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH

COMPARATIVE BIOSCIENCES, INC.

Premier Preclinical Contract Research Organization

- 20 years of experience
- Conveniently located in the heart of Silicon Valley, amidst many biotech companies
- State of the art, purpose-built facility
- Approximately 30 employees
- Highly experienced staff
- GLP, OECD, FDA, USDA, OLAW
- AAALAC Accreditation

Scientific Overview

We specialize in developing a custom study plan in order to best meet your preclinical research needs and prepare for regulatory submission.

- GLP and Non-GLP
- Toxicology
- Efficacy
- Pharmacokinetics
- Pharmacology
- Oncology Studies
- In-house histopathology, immunohistochemistry & TCR



Our Staff

Study Directors

- PhD level scientists
- Appointed by management for each job
- Serves as single point of control and is responsible and accountable for study conduct and scientific interpretation
- Experienced, attentive, and communicative
- Rapid study initiation and report preparation

- Research Associates
 - Bachelor level scientists
 - Extensive technical training
- Quality Assurance
 - Rigorous Training Program



CBI Animal Facility

• Dedicated Rooms:

- Six small animal and four large animal rooms
- Two procedure rooms, two surgery rooms
- Two rooms with ventilation for immuno-compromised animals

• Air Quality Systems:

- HVAC, light control in each room
- 10-15 air changes per hour with positive air flow and filtered air

• Cleanliness:

- Dual corridor system with pass-thru Basil cage washer
- Daily environmental monitoring
- Regular disease, bacterial and water surveillance
- 24/7 Staff





- **Mice and Rats:** transgenic, knockout, immunocompromised, and wild-type strains
- Guinea Pigs, Hamsters, Gerbils
- **Rabbits:** New Zealand White, Dutch Belted
- Ferrets
- Chinchillas
- **Dogs:** Lab Beagles
- Mini-Pigs: Gottingen, Yucatan





- Small molecules
- Biologics
 - Peptides
 - Antibodies
 - Vaccines
 - siRNA & Nucleic Acids
- Stem cells & cell therapies
- Devices
- Device and drug combinations
- Regenerative medicine



Toxicology Studies

- GLP and Non-GLP studies
- Single-dose and multiple-dose studies
- All routes of administration
- Acute & chronic studies
- Discovery and Investigative toxicology
- Non-standard routes of administration
- Complete, prompt reports



Pharmacokinetic Studies

- GLP and Non-GLP studies
- Single-dose or multiple-dose studies
- Sample analysis from blood, urine, CSF, feces
- Measure Cmax, Tmax, AUC
- Metabolic and pharmacodynamics studies
- Non-standard routes of administration



Pharmacology and Efficacy Studies

- Pharmacology and efficacy modeling in multiple areas
- Custom model development
- Surgical modeling
- Investigative studies
- Combination GLP efficacy and toxicology



Pharmacology and Efficacy Studies

- Animal Disease Models for Multiple Indications
 - Ocular
 - Otic
 - Cardiovascular
 - Inflammation
 - Dermatology
 - Arthritis
 - Allergic and Immune
 Mediated studies
 - Wound healing and scarring

- Fibrotic: skin and lung
- Anti-infective studies
- Oncology
- Botulinum toxin
- Central nervous system
- Regenerative medicine
- Osteogenesis imperfecta/
 Osteoporosis



Histopathology Services

• Complete In House Laboratories

- Paraffin, cryotomy, plastic
- Immunohistochemistry
- Special Stains
- **Toxicology Pathology**: Necropsy, Histopathology, Histomorphometry
- **Molecular Pathology**: Procurement, embedding and sectioning of tissue studies
- Highly skilled staff
 - Trained technicians
- Validated pathology data acquisition system
- Evaluation and report by Board Certified Pathologist

Investigative Pathology

- **Histomorphometry:** quantitative analysis of IHC stained slides; Capillary angiogenesis in whole mount Retina , and Fibrosis
- Tissue cross reactivity studies (TCR)
- Immunofluorescence and Confocal laser scanning microscopy, Transmission electron microscopy (TEM)
- Synthesis of DNA/RNA Probes
- In situ Hybridization (CISH and FISH)
- Histopathology evaluation by board certified pathologist
- Report with representative photomicrographs
- Archiving: Report, Specimens, Slides, FFPE, FROZEN and Plastic blocks



A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH

COMPARATIVE BIOSCIENCES, INC.

Tour of Facility


Oncology Study Capabilities


CBI's experience includes

- Establish in-house xenograft with numerous cell lines
- Human xenograft implants (PDX)
- Rodent syngeneic implants
- Orthotopic Implants
- Metastatic models
- Angiogenesis models
- Biomarker Discovery and Validation
- In vitro assays



Xenograft Model: Study Design





Available Cell Lines Include:

- Brain: U87, CMLV
- Breast: MCF7, MDA MB-231, MDA-MB-435, MDA-MB-468, T-47D
- Cervical: C33A, Swiss HeLa
- **Colon**: KM12, COLO 205, HCT-15, HT-29, HCT-116, LS174T, DLD-1, LS1034
- Epidermoid Carcinoma: A431
- Fibrosarcoma: HT-1080
- **Gastric Carcinoma**: MKN-45, SNU-638, SNU-620, SNU-5, Hs746T
- Glioma: GOGUVM, U87MG
- Head and Neck: Hep-2 (contaminated w/ HeLa)
- Lung: A549, NCI-H69, NCI-H226, NCI-H441, NCI-H460
- Melanoma: LOX-IMVI, SKMEL-28
- Myeloid: Daudi Cell, Kasumi-1, Jeko, Rabbit VX2, HL60
- **Ovarian**: SK-OV-3, OVCAR-3, OVCAR-5, ES-2
- Pancreas: CFPAC-1, PANC-1, BxPC-3, MIA PaCa-2
- Prostate: CRW22, LNCaP, PC-3, DU-145, MDA PCa 2b
- Renal: CAKI-1, A498, SN12C, ACHN, 769-P

Xenograft Model: Study Design


Supporting Capabilities for Assessment of Anticancer Candidates include:


- Pharmacokinetics including radiolabeling
- Maximum tolerated dose, acute and subacute toxicity
- Hematology and clinical chemistry
- Histopathology including GLP toxicological pathology
- Immunohistochemistry, immunofluorescence, in situ hybridization
- Antibody Cross Reactivity Studies (research and GLP)



Xenograft Model: Histological Results

- Histopathology is a powerful tool in the assessment of anti-cancer agents
 - Complete necropsy, organ weights, clinical chemistry
 - Routine paraffin sectioning and special stains
 - Cryotomy and Immunohistochemistry including: TUNEL, PCNA, Transferrin, Angiogenesis, Markers Necrosis
 - In Situ Hybridization, Fluorescent Angiography, Plastics
 - Antibody Cross Reactivity
 - Digital Image Analysis
 - ACVP Board Certified Veterinary Pathologist







PDX Mouse Models

• Patient derived tumor xenografts (PDX)

- Cancerous tissue from a patient's primary tumor is implanted directly into an immunodeficient mouse.
- Test article efficacy will be tested on tumor bearing mice.
- Partnership is local collaborators that can provide custom PDX lines for studies



Syngenic Tumor Model



- Syngeneic tumor models utilize
 immunocompetent animals as the
 host, enabling the efficacy evaluation
 of cancer therapeutic.
 - Breast Cancer: 4T1 (BALB/c), DB7
 - Colon Cancer: C51, CT-26
 - Lung Cancer: Lewis lung carcinoma
 - Melanoma and Ocular melanoma: B16F10, B16F1 (C57B6)
 - Renal Cell Carcinoma: RENCA
 - Teratoma: F9




Orthotopic Tumor Model


- Implantation of tumor cells into the organ of origin allows organotypical interaction between tumor cells and surrounding stroma.
- Tumor cells are implanted surgically at target sites
 - Pancreas
 - Prostate
 - Spleen (LS174T)
 - Brain



Metastatic Tumor Model

- Certain tumor lines readily metastasize
- Metastases may be measured or counted
- Metastatic lines LS174T, MCF-7, HT29 well established
- B16-F10 metastatic ocular melanoma






Metastatic Lung Imaged by microCT


3D Volumetric

images


Normal Mouse Lung



Tissue Volume




Airway Volume




CT Slice


EBC-1 Bearing Mouse Lung



Tissue Volume



Airway Volume





- Mechanism of Angiogenesis critical area of cancer research
- Neovascularization of tumor, metastases, implants, corneal implants may be assessed
 - Fluorescent angiography
 - Histopathology
 - Immunohistochemistry
 - Immunofluorescence
- Knockout and transgenic mice with vascular defects available
- Corneal Micropocket in Mice and Rats
- Analytical peptide
 - apoptosis tracers in vivo or ex vivo stain apoptotic cells prior to explanation and analysis of the tissue

Angiogenesis

- Chick Chorioallantoic Membrane (CAM) assay; Stimulation and Inhibition of angiogenesis
- *Ex-Vivo* angiogenesis; Tube formation






Angiogenesis – Corneal Micropocket Assay

- The study and development of anti-angiogenic therapies depends on reliable and reproducible stimulation models of neovascular response. The corneal micropocket provides a robust and rapid assay
- Hydron pellet preparation with varying basic fibroblast growth factor (bFGF) concentrations, which is adjusted for specific study requirements
- Pellet is surgically implanted into the base of the corneal micropocket
- Histologic examination records neovascularization in the cornea using a slit lamp microscope connected to a camera
- Intravital fluorescent angiography is conducted
- Pharmacokinetics of aqueous or vitreous
- Histopathology and immunohistochemistry



Biomarker Discovery and Validation

- Target discovery
- Mechanism of action using knockdown and over expression of target molecule
- Human primary cell assays (using HUVEC or human primary cells from patients)
- Enzyme immunoassay (EIA) for Collagen, Cytokines
- TUNEL, MTT, ADCC, CDC assay
- Bioluminescence and MicroPET
- Protein analytic ELISA, WB, IP
- patients)
- Enzyme immunoassay (EIA) for Collagen,
- Protein analytic ELISA, WB, IP



Overview of Biomarker method validation


Quantitative Molecular Imaging


- Compelling Advantages of this New Additional Capability
 - Disease staging
 - Decreased animal usage
 - Decreased drug needed
 - Imaging complements histology
 - Data mining 4D image replicas can be re-interrogated
 - FDA endorsed, IND accepted becoming expected, Critical Path Initiative




SPECT/CT Tumor Imaging

A wide range of biomarker and therapeutic biologics have been imaged and quantitated by SPECT. The longer half-life of SPECT radionuclides compared to PET allow for imaging over several weeks.





¹²³I - MAB



⁹⁹mTc - VEGF

¹²³I-metaiodobenzylguanidine(MIBG) microSPECT/CT and FDGPET comparison in a mousemodel of neuroblastoma




Imaging Tox (apoptosis) by SPECT

- Many cancer drugs have off target toxicity at lower concentrations that are undetected in standard preclinical GLP tox studies.
- Functional organ toxicity at early stages can only be determined in vivo by imaging.
- Apoptosis is an early indicator of cell toxicity long before even functional damage can be detected.
- In this example the cancer drug doxorubicin induced apoptosis not only in the tumor but in a variety of normal organs.



Dox





CONTROL


Drug induced apoptosis imaged with ⁹⁹mTc – annexin V – tumor model


PET PK (Dynamic Imaging) in Cancer Tissue

An alternative when not possible by conventional PK (Blood)











FLI Imaging of Tumor Markers

Longitudinal Concentration Analysis






- Integrisence is an αv integrin receptor marker on tumor blood vessels and tumor cells.
- Prosence is a cathepsin D activated fluorophore. Cathepsin D is overexpressed in many tumors.

BLI Imaging

In Vivo Transfected Liver



Photon Intensity Map: In Vivo transfection of liver cells by HDTV procedure. Mouse was transfected 7 days earlier with pCBA-Luc. Image was acquired following ip injection of Luciferin. Data expressed as p/s/cm2/sr

Cells can be labeled in vivo as above or labeled in vitro and injected in vivo as in cancer or stem cell studies



Service and Quality

- Thoroughness in planning and execution is key to a successful study. All protocols are vetted and approved by multiple personnel. Our QAU has a rigorous training program. All non-GLP studies are conducted in the spirit of GLP.
- We believe in sound science. Our ratio of scientists to nonscientists is one of the highest in the industry. Every study director is a PhD-level scientist.
- We believe in communication. Timely responses to your inquiries and frequent updates on your study are mandatory.
- We welcome visitors. You are always welcome at CBI to meet the staff, tour the laboratory and discuss the progress and results of your study.

Summary

- CBI provides state of the art:
 - Toxicology
 - Pharmacokinetics
 - Efficacy
 - Pharmacology
 - In house histopathology
 - Imaging
- Experienced attentive and communicative study directors
- Rapid study initiation and report preparation
- Established, stable business
- Regulatory compliance
- Favorable pricing structure
- Conveniently located facility

